MVIS US Listed Pharmaceutical 25 Index ETF Overview

The MVIS US Listed Pharmaceutical 25 Index measures the performance of securities and is selected by a process. Currently, 1 ETF track the MVIS US Listed Pharmaceutical 25 Index with more than -- in ETP assets with an average expense ratio of 0.35%. The largest ETF is () by with in assets.


ETF Report

Best Of 2016: This Year's Most Innovative New ETFs

2016 has seen many new ETFs that offer new exposures or new approaches to exposures already available.

Features and News

3 Pharma ETFs For Riding M&A Wave

But not all pharmaceutical exchange-traded funds are created equal.

Features and News

ETF Morning Call: Markets Eyeing US Data

Asia mixed on China PMI; Europe up on China PMI and hopes for improved U.S. consumer confidence; U.S. futures unchanged ahead of slew of economic data.

Journal Of Indexes

AROUND THE WORLD OF ETFs

Van Eck Repackages 6 HOLDRS

ETF Report

 Some HOLDRS Closed, Some Reborn

The final 11 HOLDRS, which collectively had about $305 million in assets, were terminated on Dec. 23 by their sponsor, Merrill Lynch, Pierce, Fenner & Smith.

Features and News

Van Eck Sets Splits On 5 Former HOLDRS

Van Eck, hoping to boost liquidity, sets share splits on five of the six former HOLDRS it turned into ETFs.

ETF Report

 Van Eck Begins To Transition HOLDRS

In mid-November, Van Eck began the exchange offers under which six Merrill Lynch-sponsored exchange-traded HOLDRS securities will switch into six corresponding Market Vectors ETFs.

Features and News

Van Eck Launches ETFs That Were HOLDRs

Van Eck rolls out six ETFs that until yesterday were HOLDRs with the same tickers.